Eli Lilly has said it plans to file its anti-IL-23p19 antibody mirikizumab for approval as a treatment for Crohn’s disease next year after it hit all its targets in a phase 3 trial.
The VIVID-1 study in adults with moderately to severely active Crohn’s showed that mirikizumab achieved the primary and secondary endpoints in the study with a lower rate of serious adverse events than placebo.
